Send to

Choose Destination
World J Mens Health. 2018 Sep;36(3):248-254. doi: 10.5534/wjmh.170003. Epub 2018 May 17.

Is It Worth Treating Non-Bothering Nocturia? Results of a Multicenter Prospective Observational Study.

Author information

Department of Urology, Chonnam National University Medical School, Gwangju, Korea.
Department of Urology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.
Department of Urology, School of Medicine, The Catholic University of Korea, Seoul, Korea.
Department of Urology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.
Department of Urology, Chonbuk National University Medical School, Jeonju, Korea.
Department of Urology, Pusan National University School of Medicine, Busan, Korea.
Department of Urology, Yeungnam University College of Medicine, Daegu, Korea.
Department of Urology, Korea University College of Medicine, Seoul, Korea.
Department of Urology, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
Department of Urology, SMG-SNU Boramae Medical Center, Seoul, Korea.
Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Department of Urology, Gyeongsang National University School of Medicine, Jinju, Korea.
Department of Urology, Konkuk University Chungju Hospital, Konkuk University School of Medicine, Chungju, Korea.
Contributed equally



The purpose of this study was to evaluate the efficacy of treatment in patients with non-bothering nocturia.


In this prospective multicenter study, patients who visited hospitals for treatment of voiding symptoms were enrolled. Inclusion criteria were: 1) men >45 years, and 2) nocturia ≥2 confirmed by a three-day voiding diary. Subjects were divided into non-bothering and bothering groups based on International Consultation on Incontinence Questionnaire Nocturia (ICIQ-N) question 2b. Changes in voiding symptoms, frequency of nocturia, and bothersomeness were evaluated with international prostate symptom score (IPSS), ICIQ-N, and three-day voiding diary at 4 and 12 weeks after treatment.


A total of 48 patients in the non-bothering nocturia group and 50 patients in the bothering nocturia group who completed the 12-week treatment were analyzed. The total IPSS was decreased by 5.8 in the non-bothering group and 5.2 in the bothering group. There was no significant difference in decrease of IPSS between the two groups. Both groups showed significant reduction in discomfort of nocturia. The ICIQ-N 2b score decreased from 3.9 to 2.7 (p=0.01) in the non-bothering group and from 6.9 to 4.6 (p=0.02) in the bothering group. The number of nocturia episodes was significantly decreased in both groups.


Regardless of discomfort associated with nocturia, both groups showed significant improvement in nocturia-related discomfort and voiding symptoms. These results suggest that patients with nocturia who were unaware of its discomfort benefited from treatment.


Lower urinary tract symptoms; Nocturia; Prostatic hyperplasia; Therapeutics

Supplemental Content

Full text links

Icon for Korean Society for Sexual Medicine and Andrology Icon for PubMed Central
Loading ...
Support Center